Coronary Artery Bypass Graft Devices – Market Insights – Europe

The mature European CABG device market will contract modestly through 2026 as procedure volumes decline due to increasing use of PCI for the treatment of CAD; however, rising interest in OPCAB and minimally invasive approaches to CABG surgery will help to mitigate overall revenue declines to some extent.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for CABG devices in Europe across a 10-year period.

Surgical revascularization via CABG surgery for CAD patients is facing increasing competition from alternative treatments such as PCI and medical management. 

What is the rate of decline for CABG procedure volumes in Europe?

In which specific indications will CABG procedure volumes increase?

What impact will recent and ongoing clinical trials have on CABG procedure volumes and clinical guidelines for coronary revascularization in the Europe?

The CABG device market is highly mature, highly competitive, and dominated by several large MNCs.

Who are the companies with a major foothold in this market?

What strategies are adopted by these companies to tackle the highly competitive nature of the market?

What other factors are also presenting challenges to companies within this segment?

Price competition will limit revenue growth potential, especially in light of increased cost-consciousness among health care facilities.  

Which segments will experience the most price competition?

In which segments and to what extent will adoption of premium-priced next-generation products offset the effects of price competition? 

What strategies may CABG device manufacturers adopt to address the increasing cost-consciousness among health care facilities?